What are the treatment options for patients with duodenal cancer who have progressed on FOLFIRINOX?

The quality of evidence for almost all treatments in small bowel adenocarcinomas is poor to some extent. First, I would look at the NGS data I am sure you have or can obtain easily for a molecular treatment if applicable (TMB > 10 = pembrolizumab, MSI-H = checkpoint inhibitor, NTRK = e.g. entrectinib, RET = Selpercatinib, HER2 = fam-trastuzumab deruxtecan, KRAS G12C = sotorasib or adagrasib, BRAF V600E = dabrafenib + trametinib).

Assuming none of those rare findings, you could try and treat as co...